NeuroCores is a spin-out company from a prestigious Japanese institution founded by the National Agriculture and Food Research Organization.
We have since developed a synthetic plasmalogen, KIT-13, with the aim of treating neurological disorders and neurodegenerative diseases caused by neuroinflammation and mitochondrial dysfunction.
In Rett syndrome mouse models, KIT-13 has demonstrated safety and potent efficacy, improving neuromotor function and survival time.
As of March 2023, the US FDA has granted KIT-13 the Rare Pediatric Drug Designation and Orphan Drug Designation, making it eligible for a pediatric priority review voucher.
Founder
Founder/CEO
Chief of Staff
C. Kanemaru
Scientific Advisors
D. Hartman, PhD
S. Mawatari, MD, PhD
S. Hossain, PhD
T. Okauchi, PhD
M. Honsho, PhD
Chief Business Officer
Christopher Aleong
Chief Finance Officer
B.Smith
Legal Advisor
D. Blanchard, JD
There are very few treatment options for neurodegenerative diseases and rare pediatric neurological disorders.
One of the underlying mechanisms of these conditions is Plasmalogen deficiency and the consequent neuroinflammation.
With powerful in vivo and human data, we are currently developing plasmalogen derivatives as safe and effective treatments for rare neurological and neurodegenerative diseases such as Rett Syndrome and Alzheimer’s disease.
Copyright © 2024 Neurocores - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.